470 related articles for article (PubMed ID: 26628580)
1. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of biological agents in patients with systemic juvenile idiopathic arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2021 Mar; 59(3):239-246. PubMed ID: 33191906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
7. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials.
Amarilyo G; Tarp S; Foeldvari I; Cohen N; Pope TD; Woo JM; Christensen R; Furst DE
Semin Arthritis Rheum; 2016 Dec; 46(3):312-318. PubMed ID: 27989499
[TBL] [Abstract][Full Text] [Related]
8. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.
Cabrera N; Avila-Pedretti G; Belot A; Larbre JP; Mainbourg S; Duquesne A; Janiaud P; Kassai B; Cucherat M; Lega JC
Rheumatology (Oxford); 2020 Sep; 59(9):2226-2236. PubMed ID: 32449926
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
10. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
11. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
[TBL] [Abstract][Full Text] [Related]
12. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab for treating juvenile idiopathic arthritis.
Turnier JL; Brunner HI
Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
[TBL] [Abstract][Full Text] [Related]
15. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
[TBL] [Abstract][Full Text] [Related]
19. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
20. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
